NCT06690983 · RECRUITING
Tau PET/CT in Various Tau-Related Disease Patients
This trial is testing a radioactive imaging agent called 18F-S16/T807, used in a PET/CT brain scan, to see how well it detects tau protein deposits in people with tau-related neurological diseases. The phase is unspecified, and details are limited. The core question is whether this scan is a reliable diagnostic tool — not a treatment of any kind.
Eligibility criteria
Inclusion Criteria: - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-02-11